M ycoplasma genitalium infections are increasingly recognized as an important cause of bacterial sexually transmitted diseases in the United States; however, estimates of the infectious burden differ. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Prevalence estimates range from 1.0% among a screening population of adolescent men and women 1, 2 to as high as 16 .3% and 17.2% among symptomatic and asymptomatic women and men, respectively. 3 All 3 of those studies included participants from across the United States. The prevalence of M. genitalium has been reported to be as high as 22.4% among adolescent women from Cincinnati. 4 Several studies have found a higher prevalence of M. genitalium infection than Trichomonas vaginalis, Neisseria gonorrhoeae, or Chlamydia trachomatis.
5,8,10
Mycoplasma genitalium infections have also been consistently associated with urethritis in men 11, 12 as well as cervicitis, pelvic inflammatory disease, and preterm birth in women. 12, 13 Given those sequela of untreated or inadequately diagnosed infection, the emergence of antimicrobial resistance in M. genitalium has caused concern.
11 From 1 study in the United States, the prevalence of macrolide resistance in men and women is estimated to be 50% and 42%, respectively. 3 A rapid assay for the simultaneous detection of M. genitalium and mutations associated with azithromycin resistance has been developed. 14, 15 That assay is a single well-rapid multiplex test detecting the pathogen M. genitalium, as well as the 5 most common mutations in the 23S rRNA gene (A2058G, A2059G, A2058T, A2058C, and A2059C, Escherichia coli numbering) associated antimicrobial resistance to azithromycin. The assay is compatible with multiple extraction platforms and real-time polymerase chain reaction machines. In a clinical study, that assay has been shown to have 98.5% sensitivity and 100.0% specificity for detection of M. genitalium, 15 as well as a 99.1% sensitivity and 98.5% specificity for detection of mutations associated with azithromycin resistance. 14 Evidence is lacking regarding the benefits of screening for M. genitalium infection. In addition, there are currently no Food and Drug Administration-approved assays for M. genitalium. Furthermore, there are no current screening recommendations in the United States. However, the Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines added M. genitalium infection as an emerging issue in 2015, and specify that M. genitalium infection should be suspected in cases where urethritis is persistent or recurrent. 11 To further understand the prevalence of M. genitalium infection, we aimed to characterize the infection prevalence as well as prevalence of mutations associated with azithromycin resistance at the University of California Los Angeles using a rapid genotypic assay.
METHODS
For our exploratory study, we collected all remnant DNA from consecutive clinical specimens, including urine samples, and urethral, vaginal, cervical, pharyngeal and rectal swab specimens submitted to the University of California Los Angeles Health System Clinical Microbiology Laboratory. Those specimens were submitted between March and April 2017 for standard of care N. gonorrhoeae and C. trachomatis nucleic acid amplification testing. The University of California Los Angeles Health System is comprised of 2 hospitals, 2 emergency departments, and over 150 primary care clinics serving approximately 500,000 patientvisits each year.
The University of California Los Angeles Health System uses the Cobas 4800 CT/NG assay (Roche Molecular Systems, Pleasanton, CA), which is used to extract and amplify N. gonorrhoeae and C. trachomatis DNA from a clinical swab specimen. As part of routine clinical practice, internal C. trachomatis and N. gonorrhoeae DNA controls were added to each individual sample well before the automated sample preparation, were amplified, and were detected simultaneously to monitor the entire process to ensure adequate DNA amplification. An individual sample in which the control was not within the specified range established was considered invalid. Additionally, the limit of C. trachomatis and N. gonorrhoeae detection in different anatomical specimens ranges from 10 to 200 Elementary Bodies/mL and 0.2 to 3.0 Colony Forming Units/mL, respectively, per the Cobas 4800 CT/NG assay product insert. Although it is unknown if that translates to an equivalent level of detection for M. genitalium, it was assumed that if there was sufficient bacterial DNA extracted (as evaluated by the internal control validation), the presence of M. genitalium DNA would likely be detected by the sensitive assay described below. Remnant DNA specimens from the Cobas 4800 CT/NG assay were de-identified and stored at −20°C for up to 22 days before subsequent testing.
DNA specimens were shipped to Australia in the same media in which they were extracted and directly subjected to M. genitalium testing as well as testing for mutations associated with azithromycin resistance using the ResistancePlus MG (550) kit (SpeeDx Pty. Ltd., Sydney, Australia) on the Applied Biosystems 7500 platform (Thermo Fisher Scientific, Waltham, MA). A positive M. genitalium control template was used to ensure DNA amplification was performing as expected. All M. genitalium positive specimens were subjected to genotype sequencing using previously published primers. 16 Sanger sequencing was performed at Ramaciotti Centre for Genomics (University of New South Wales, Sydney, Australia). Of note, the ResistancePlus MG (550) kit has not been approved by the Food and Drug Administration in the United States, thus this research is a nonclinical investigational use of this assay.
We also gathered data on anatomic site of specimen collection, N. gonorrhoeae and C. trachomatis nucleic acid amplification test results, and collection date. Specimens with incomplete data were not used in the analysis.
We then determined the prevalence of M. genitalium infection as well as the frequency of mutations associated with azithromycin resistance. We also report the prevalence of infection and azithromycin resistance mutations by anatomic site from which the specimen was collected, as well as the 95% confidence intervals (CIs) for those proportions including a continuity correction. All analyses were performed using STATA software version 14.2 (College Station, TX). The University of California Institutional Review Board determined that the testing of de-identified remnant clinical specimens and the review of de-identified data did not constitute human subjects' research.
RESULTS
We analyzed 500 specimens. The Figure 1 shows the prevalence of infection by anatomic site. Overall 10 (2.0%; 95% CI, 1.1%-3.8%) samples tested positive for M. genitalium. One (0.2%) of 500 specimens tested positive for both N. gonorrhoeae and C. trachomatis. No N. gonorrhoeae or C. trachomatis-positive specimen tested positive for M. genitalium DNA.
Of the 10 specimens that tested positive for M. genitalium, 8 (80.0%; 95% CI, 44.2%-96.5%) had at least one mutation associated with azithromycin resistance by the ResistancePlus MG (550) kit. Of those, 3 (37.5%) were from urine samples, 3 (37.5%) were from rectal specimens, and 2 (25.0%) were from vaginal/cervical samples.
On genotype sequencing, all 8 specimens testing positive for a mutation by the ResistancePlus MG (550) kit were confirmed to have a mutation associated with azithromycin resistance (Table 1) . The 2 remaining specimens that tested positive for M. genitalium with no resistance mutation were unable to be sequenced.
DISCUSSION
We report the prevalence of M. genitalium infection among remnant DNA samples collected from persons being tested for N. gonorrhoeae and C. trachomatis at the University of California Los Angeles Health System. We also report the prevalence of azithromycin resistance among those infections. The overall prevalence of infection is similar to past reports of M. genitalium infection from the general population reported in the United States. 1, 2 However, the prevalence of M. genitalium among populations at Figure 1 . Prevalence of Mycoplasma genitalium, Neisseria gonorrhoeae, and Chlamydia trachomatis infections among remnant DNA specimens collected from men and women undergoing testing for Neisseria gonorrhoeae and Chlamydia trachomatis. By anatomic site, the prevalence of azithromcyin resistance among M. genitalium positive specimens was 75% (rectal), 75% (urine), and 100% (cervix/vaginal). * Includes 4 genital swabs from an unspecified anatomic site, 4 pharyngeal swabs, and 1 conjunctival swab.
higher risk for sexually transmitted infections has been reported to be as high as 20.5% from a multicenter study in the United States. 17 Our prevalence estimates were lower for urethral 5 and cervical/vaginal 4, 8 infections than prior estimates. We also found a higher prevalence of rectal M. genitalium infection than the 5% prevalence reported among men who have sex with men presenting to a sexually transmitted diseases clinic in San Francisco. 18 From that same study, the prevalence of rectal T. vaginalis was 1%, N. gonorrhoeae was 11%, and C. trachomatis was 10%. A recent report found a higher prevalence of rectal C. trachomatis (21%) and N. gonorrhoeae (40%) infections than rectal M. genitalium infections (17%) among men who have sex with men. 19 The wide range of prevalence estimates in the literature likely reflects differing risk groups as well as different detection methods (eg, polymerase chain reaction vs. transcription-mediated amplification). 2, 3, 5, 7, 17, 20 The prevalence of resistance mutations among our population was concerning because azithromycin is the first line recommended treatment, and antibiotic selection is already limited. 21 Mycoplasma genitalium is not easily treated with tetracyclines. 21 Moxifloxacin has been shown to be effective against azithromycin-resistant strains of M. genitalium
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; however, concern for fluoroquinolone resistance and moxifloxacin treatment failure is increasing; 1 study reported cure in only 88% of macrolide-resistant M. genitalium infections after treatment with moxifloxacin. 23 A previous study among the general population in the United States reported a 51% and 42% prevalence of azithromycinresistant M. genitalium infections among women and men, respectively. 3 Notably, that study also reported a considerably higher prevalence of M. genitalium infection overall than was found in other surveillance studies among the general population. Therefore, that population may be at a higher risk for sexually transmitted infections.
Worldwide, similar estimates of macrolide-resistant M. genitalium infections have been reported. A Danish nationwide survey found a 38% prevalence of macrolide resistance among M. genitalium infections in the general population, and a 43% prevalence of resistance among infections diagnosed at sexually transmitted diseases clinics. 24 A prior report from Australia using the same assay used in the present study demonstrated an 81% prevalence of azithromycin-resistant M. genitalium infections among men presenting to a sexual health center, with all rectal swabs testing positive for azithromycin resistance; the prevalence of azithromycin resistance mutations among women from the same population was 30%. 15 In Greenland, the prevalence of macrolide-resistant M. genitalium infections may be as high as 100% in the general population. 25 The prevalence of M. genitalium infection in our sample was comparable to the prevalence of N. gonorrhoeae and C. trachomatis infections. Other studies have reported similar findings, 1,2 whereas some studies have even reported a higher prevalence of M. genitalium compared to T. vaginalis, N. gonorrhoeae, or C. trachomatis. One study reported a higher prevalence of M. genitalium (17%) among men, 3 another reported a higher prevalence of M. genitalium among women with cervicitis (29%), 5 and another reported a higher prevalence of M. genitalium (8%) compared with N. gonorrhoeae or C. trachomatis among participants with symptoms of a sexually transmitted infection. 8 A high prevalence of infection is necessary but not a sufficient condition to support screening recommendations; other conditions must apply, such as demonstration that screening favorably improves prognosis. Further evidence is needed to support any recommendation for increased screening. Such research should aim to characterize the population at highest risk of infection, provide evidence of the benefits of screening, and document the risks of screening. 26 Beyond screening, however, testing of symptomatic patients for M. genitalium infection has been hindered for many years because it is difficult to culture the bacteria. The introduction of molecular assays for the detection of infection and resistance mutations may facilitate earlier and more appropriate treatment. Molecular assays for the diagnosis of M. genitalium have been developed. 10, 14, 27 Given the reported health consequence of untreated infection, 12, 13 we advocate for including M. genitalium testing in individuals with urethritis, as well as testing for azithromycin resistance among those that test positive for M. genitalium.
The use of genotypic assays for guiding antimicrobial selection may reduce the selective pressure for antimicrobial resistance by improving antimicrobial stewardship. 28 Improved diagnostics for M. genitalium infection and for determining antimicrobial susceptibility will be important for optimal clinical management. Several rapid molecular assays for the prediction of antimicrobial susceptibility have been developed for other organisms, and are used clinically to guide therapy for Mycobacterium tuberculosis, 29 Staphylococcus aureus, 30 carbapenem-resistant Enterobacteriaceae, 31 and N. gonorrhoeae. 32 All have been shown to be highly sensitive and specific.
STRENGTHS AND LIMITATIONS
One strength of our study was the use of consecutive remnant specimens, which reduces participation bias. Our study does have limitations, however. Primarily, we did not perform confirmatory culture on the specimens that tested positive for M. genitalium infection. Similarly, it was assumed that successful bacterial DNA extraction for C. trachomatis and N. gonorrhoeae (as determined by the internal control) would result in sufficient M. genitalium DNA extraction, however that assumption has not been validated and it is possible our results underestimate the prevalence of M. genitalium infection. Additionally, the internal amplification controls for the Cobas 4800 do not control for adequate specimen collection. Furthermore, we were unable risk stratify our population as we performed analysis of only deidentified data and clinical or behavioral information was not available to us.
We report the prevalence of M. genitalium infection and mutations associated with azithromycin resistance from consecutive remnant clinical samples collected from men and women at the University of California, Los Angeles being tested for N. gonorrhoeae and C. trachomatis infection. The prevalence of M. genitalium infection in our population varied by anatomic site of infection. The prevalence of mutations associated with azithromycin resistance in the specimens that tested positive for M. genitalium was higher than expected. Those findings warrant further investigation into the prevalence of M. genitalium infection and local azithromycin resistance rates. 
